January collaboration gives Wyeth the right to develop and commercialize selected antibodies.
Wyeth Pharmaceuticals decided to extend its evaluation of selected mAbs from Raven biotechnologies. The companies entered an agreement in January, wherein Wyeth had the option to obtain an exclusive license to develop and commercialize selected mAbs to a specified target.
The antibodies included in the agreement were discovered using Raven’s immunization technology and tumor-derived stem-cell lines and were screened to select antibodies that are active alone or in a conjugated form.
“Raven has multiple anti-cancer antibody drug candidates in our pipeline,” reports George F. Schreiner, M.D., Ph.D., CEO. “Collaborations such as this are a critical part of our strategy to rapidly advance the most promising candidates into the clinic.”